Spero Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Spero Therapeutics, Inc. (SPRO) reported Increase (Decrease) in Deferred Revenue of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-12
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$12.57M.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$12.59M.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$370.00K.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$933.00K, a 104.26% decline from fiscal 2022.
- Spero Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $21.89M, a 105.69% increase from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | -$12.57M derived: sum of 3 quarters · filed 2026-08-12 | -$12.57M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | -$12.57M derived: sum of 2 quarters · filed 2026-05-13 | -$12.57M derived: sum of 3 quarters · filed 2026-05-13 | -$12.57M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$12.57M derived: sum of 2 quarters · filed 2026-03-26 | -$12.57M derived: sum of 3 quarters · filed 2026-08-12 | -$12.59M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | -$12.00K 10-Q · filed 2025-11-13 | -$63.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$12.00K 10-Q · filed 2026-08-12 | -$63.00K derived: sum of 3 quarters · filed 2026-08-12 | -$128.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$12.00K 10-Q · filed 2026-05-13 | -$63.00K derived: sum of 2 quarters · filed 2026-05-13 | -$128.00K derived: sum of 3 quarters · filed 2026-05-13 | -$241.00K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$116.00K derived: sum of 2 quarters · filed 2026-03-26 | -$229.00K derived: sum of 3 quarters · filed 2026-03-26 | -$370.00K 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | -$65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$178.00K derived: sum of 2 quarters · filed 2025-11-13 | -$319.00K 10-Q · filed 2025-11-13 | -$543.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$254.00K 10-Q · filed 2025-08-12 | -$478.00K derived: sum of 3 quarters · filed 2025-08-12 | -$695.00K derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$141.00K 10-Q · filed 2025-05-13 | -$365.00K derived: sum of 2 quarters · filed 2025-05-13 | -$582.00K derived: sum of 3 quarters · filed 2025-05-13 | -$850.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$441.00K derived: sum of 2 quarters · filed 2025-03-27 | -$709.00K derived: sum of 3 quarters · filed 2025-03-27 | -$933.00K 10-K · filed 2025-03-27 | $29.01M 10-K · filed 2024-03-13 | |||
| 2023-09-30 | -$217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$485.00K derived: sum of 2 quarters · filed 2024-11-14 | -$709.00K 10-Q · filed 2024-11-14 | $5.09M 10-Q · filed 2023-11-13 | $17.66M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$492.00K 10-Q · filed 2024-08-05 | -$1.53M 10-Q · filed 2023-08-10 | $17.88M derived: sum of 3 quarters · filed 2024-08-05 | $21.79M derived: sum of 4 quarters · filed 2024-08-05 | |||
| 2023-03-31 | -$224.00K 10-Q · filed 2024-05-15 | -$740.00K 10-Q · filed 2023-05-11 | $18.14M derived: sum of 2 quarters · filed 2024-05-15 | $22.06M derived: sum of 3 quarters · filed 2024-05-15 | $21.91M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $22.29M derived: sum of 2 quarters · filed 2024-03-13 | $22.14M derived: sum of 3 quarters · filed 2024-03-13 | $21.89M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.77M derived: sum of 2 quarters · filed 2023-11-13 | $3.52M 10-Q · filed 2023-11-13 | $3.27M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$393.00K 10-Q · filed 2023-08-10 | -$648.00K derived: sum of 3 quarters · filed 2023-08-10 | $11.61M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$246.00K 10-Q · filed 2023-05-11 | -$501.00K derived: sum of 2 quarters · filed 2023-05-11 | $11.75M derived: sum of 3 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | -$255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $12.00M derived: sum of 2 quarters · filed 2023-03-30 | $10.64M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | $12.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.90M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$1.36M 10-Q · filed 2022-08-10 | |||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |